Physician profile
Ovais Raza
NPI 1386697761
$686.22
in general payments reported to CMS, 2019-2025
9 companies · $93.46 in 2025
The $93.46 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $29.00 · 2021: $138 · 2022: $58.20 · 2023: $83.79 · 2024: $161 · 2025: $93.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $221.34 | 2019-2023 | Camzyos, Eliquis |
| Abbott Laboratories | $196.82 | 2021-2025 | Diamondback Coronary, Xience Skypoint, Mitraclip |
| Edwards Lifesciences Corporation | $106.49 | 2021-2023 | Sapien 3 Ultra Resilia |
| Amgen INC. | $37.86 | 2024 | Repatha |
| Heartflow, INC. | $32.04 | 2024 | |
| Arbor Pharmaceuticals, INC. | $30.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.99 | 2019-2023 | |
| Cardiovascular Systems INC. | $21.11 | 2019 | |
| Boston Scientific Corporation | $14.93 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ovais Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.